DOSING & ADMINISTRATION FOR DARZALEX (daratumumab)
|
|
- Audra Pitts
- 6 years ago
- Views:
Transcription
1 JUNE 2017 UPDATE DOSING & ADMINISTRATION FOR DARZALEX (daratumumab)
2 Indications and mechanisms of action 1 How DARZALEX is supplied DARZALEX (daratumumab) is indicated: in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are doublerefractory to a PI and an immunomodulatory agent DARZALEX is a first-in-class monoclonal antibody that targets CD38 1 CD38 is expressed on hematopoietic cells, other cell types and tissues, and is over-expressed on multiple myeloma cells 1,2 DARZALEX inhibits tumor cell growth through immunemediated, direct on-tumor, and immunoregulatory actions. DARZALEX may also have an effect on normal cells Warnings and precautions include: infusion reactions, interference with serological testing, neutropenia, thrombocytopenia, and interference with determination of complete response. In patients who received DARZALEX in combination with lenalidomide and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: upper respiratory tract infection (65%), infusion reactions (48%), diarrhea (43%), fatigue (35%), cough (30%), muscle spasms (26%), nausea (24%), dyspnea (21%) and pyrexia (20%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions were pneumonia (12%), upper respiratory tract infection (7%), influenza (3%) and pyrexia (3%). DARZALEX in combination with lenalidomide and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were neutropenia (36%) and lymphopenia (42%). Dosage form and strengths 1 DARZALEX is a colorless to pale yellow, preservative-free solution for intravenous (IV) infusion DARZALEX is supplied in single-use vials 100 mg/5 ml (20 mg/ml) 1 Storage mg/20 ml (20 mg/ml) Store in a refrigerator at 2 C to 8 C (36 F to 46 F) Do not freeze or shake. Protect from light. This product contains no preservative In patients who received DARZALEX in combination with bortezomib and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: peripheral sensory neuropathy (47%), infusion reactions (45%), upper respiratory tract infection (44%), diarrhea (32%), cough (27%), peripheral edema (22%), and dyspnea (21%). The overall incidence of serious adverse reactions was 42%. Serious adverse reactions were upper respiratory tract infection (5%), diarrhea (2%) and atrial fibrillation (2%). DARZALEX in combination with bortezomib and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were lymphopenia (41%) and thrombocytopenia (28%). 2
3 (cont d) In patients who received DARZALEX as monotherapy, the most frequently reported adverse reactions (incidence 20%) were: infusion reactions (48%), fatigue (39%), nausea (27%), back pain (23%), pyrexia (21%), cough (21%), and upper respiratory tract infection (20%). Serious adverse reactions were reported in 51 (33%) patients. The most frequent serious adverse reactions were pneumonia (6%), general physical health deterioration (3%), and pyrexia (3%). DARZALEX as monotherapy: treatment-emergent Grade 3-4 hematology laboratory abnormalities >20% was lymphopenia (30%). In patients who received DARZALEX in combination with pomalidomide and dexamethasone, the most frequent adverse reactions (>20%) were fatigue (50%), infusion reactions (50%), upper respiratory tract infection (50%), cough (43%), diarrhea (38%), constipation (33%), dyspnea (33%), nausea (30%), muscle spasms (26%), back pain (25%), pyrexia (25%), insomnia (23%), arthralgia (22%), dizziness (21%), and vomiting (21%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions reported in 5% patients included pneumonia (7%). DARZALEX in combination with pomalidomide and dexamethasone: treatment-emergent hematology Grade 3-4 laboratory abnormalities 20% were anemia (30%), neutropenia (36%, 46%), and lymphopenia (45%, 26%). 3
4 DARZALEX (daratumumab) + lenalidomide + dexamethasone (DRd) DOSING & SAFETY
5 DARZALEX (daratumumab) + Rd dosing Important information 1 DARZALEX should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur Recommended dosage and schedule 1 If a planned dose of DARZALEX is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval DARZALEX is given as an intravenous (IV) infusion after dilution at 16 mg/kg of actual body weight, with pre- and post-infusion medications See table on next page Revlimid (lenalidomide) is given orally on days 1 21 of each cycle* Dexamethasone 40 mg is given orally or IV once a week On DARZALEX infusion days, 20 mg of the dexamethasone dose was given as a pre-infusion medication and the remainder given the day after the infusion For patients on a reduced dexamethasone dose, the entire 20-mg dose was given as a DARZALEX pre-infusion medication Revlimid is a registered trademark of Celgene Corporation. * Please refer to the lenalidomide Prescribing Information for more detailed information about lenalidomide dosing. Dexamethasone dosing may be modified for various patient populations. Please see the DARZALEX Prescribing Information for more information. Infusion Reactions DARZALEX can cause severe infusion reactions. Approximately half of all patients experienced a reaction, most during the first infusion. Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing an infusion. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt infusion for reactions of any severity and institute medical management as needed. Permanently discontinue therapy for life-threatening (Grade 4) reactions. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion. To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients following DARZALEX infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. 5
6 DARZALEX (daratumumab) + Rd dosing schedule Dosing frequency of DARZALEX decreases throughout the course of therapy 1 DRUG INTERACTIONS Effect of Other Drugs on Daratumumab: The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab. Effect of Daratumumab on Other Drugs: The coadministration of DARZALEX with bortezomib did not affect the pharmacokinetics of bortezomib. 6
7 Established safety profile with DARZALEX (daratumumab) + Rd Safety demonstrated in combination with Rd The most frequent adverse reactions (ARs) ( 20%) with DARZALEX + Rd were infusion reactions (48%), diarrhea (43%), nausea (24%), fatigue (35%), pyrexia (20%), upper respiratory tract infection (65%), muscle spasms (26%), cough (30%), and dyspnea (21%) 1 Serious ARs with at least a 2% greater incidence in the DARZALEX + Rd arm compared to the Rd arm were pneumonia (DRd 12% vs Rd 10%), upper respiratory tract infection (DRd 7% vs Rd 4%), influenza and pyrexia (DRd 3% vs Rd 1% for each) Infusion reaction includes terms determined by investigators to be related to infusion. Severe (Grade 3) infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions (any grade; 5%) were nasal congestion, cough, chills, throat irritation, nausea and vomiting 1 Neutropenia DARZALEX may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX dose delay may be required to allow recovery of neutrophils. No dose reduction of DARZALEX is recommended. Consider supportive care with growth factors. Thrombocytopenia DARZALEX may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. DARZALEX dose delay may be required to allow recovery of platelets. No dose reduction of DARZALEX is recommended. Consider supportive care with transfusions. Grade 3 and 4 infections between study arms: 28% vs 23% with DARZALEX + Rd vs Rd alone, respectively 1 Discontinuation rates due to ARs with DARZALEX -based combination therapy were similar to Rd alone (7% vs 8%, respectively) 1 7
8 Safety demonstrated in combination with Rd * Upper respiratory tract infection, bronchitis, sinusitis, respiratory tract infection viral, rhinitis, pharyngitis, respiratory tract infection, metapneumovirus infection, tracheobronchitis, viral upper respiratory tract infection, laryngitis, respiratory syncytial virus infection, staphylococcal pharyngitis, tonsillitis, viral pharyngitis, acute sinusitis, nasopharyngitis, bronchiolitis, bronchitis viral, pharyngitis streptococcal, tracheitis, upper respiratory tract infection bacterial, bronchitis bacterial, epiglottitis, laryngitis viral, oropharyngeal candidiasis, respiratory moniliasis, viral rhinitis, acute tonsillitis, rhinovirus infection. Cough, productive cough, allergic cough. Dyspnea, dyspnea exertional. Note: ARs that occurred in 10% of patients and with at least 5% greater frequency in the DARZALEX + Rd arm are listed. 8
9 DARZALEX (daratumumab) + bortezomib + dexamethasone (DVd) DOSING & SAFETY
10 DARZALEX (daratumumab) + Vd dosing Important information 1 DARZALEX should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur Recommended dosage and schedule 1 DARZALEX is given as an intravenous (IV) infusion after dilution at 16 mg/kg of actual body weight, with pre- and post-infusion medications See table on next page Velcade (bortezomib) is administered by subcutaneous injection or IV infusion on days 1, 4, 8, and 11 of each cycle for a total of 8 cycles* Dexamethasone 20 mg is given orally once daily on days 1, 2, 4, 5, 8, 9, 11, and 12 for a total of 8 cycles On the days of DARZALEX infusion, 20 mg of the dexamethasone dose was administered as a pre-infusion medication and was continued as a pre-medication after Vd discontinuation For patients on a reduced dexamethasone dose, the entire 20-mg dose was given as a DARZALEX pre-infusion medication If a planned dose of DARZALEX is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval Interference with Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumabmediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient s serum. The determination of a patient s ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX. Type and screen patients prior to starting DARZALEX. Velcade is a registered trademark of Millennium Pharmaceuticals, Inc. * Please refer to the bortezomib Prescribing Information for more detailed information about twice-weekly bortezomib dosing. Dexamethasone dosing may be modified for various patient populations. Please see the DARZALEX Prescribing Information for more information. 10
11 DARZALEX + Vd dosing schedule Dosing frequency of DARZALEX decreases throughout the course of therapy 1 Note: Bortezomib and dexamethasone dosing should be stopped after 8 cycles. DRUG INTERACTIONS Effect of Other Drugs on Daratumumab: The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab. Effect of Daratumumab on Other Drugs: The coadministration of DARZALEX with bortezomib did not affect the pharmacokinetics of bortezomib. 11
12 Established safety profile with DARZALEX (daratumumab) + Vd Safety demonstrated in combination with Vd The most frequent adverse reactions (ARs) (>20%) with DARZALEX + Vd were infusion reactions (45%), diarrhea (32%), peripheral edema (22%), upper respiratory tract infection (44%), peripheral sensory neuropathy (47%), cough (27%), and dyspnea (21%) 1 Serious ARs with at least a 2% greater incidence in the DARZALEX + Vd arm compared to the Vd arm were upper respiratory tract infection (DVd 5% vs Vd 2%), diarrhea and atrial fibrillation (DVd 2% vs Vd 0% for each) Infusion reaction includes terms determined by investigators to be related to infusion. Severe (Grade 3) infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions (any grade; 5%) were nasal congestion, cough, chills, throat irritation, nausea and vomiting 1 Neutropenia DARZALEX may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX dose delay may be required to allow recovery of neutrophils. No dose reduction of DARZALEX is recommended. Consider supportive care with growth factors. Thrombocytopenia DARZALEX may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. DARZALEX dose delay may be required to allow recovery of platelets. No dose reduction of DARZALEX is recommended. Consider supportive care with transfusions. Grade 3 and 4 infections were similar between study arms: 21% vs 19% with DARZALEX + Vd vs Vd alone, respectively 1 Discontinuation rates due to ARs with DARZALEX -based combination therapy were similar to Vd alone (7% vs 9%, respectively) 1 12
13 Safety demonstrated in combination with Vd *Edema peripheral, edema, generalized edema, peripheral swelling. Upper respiratory tract infection, bronchitis, sinusitis, respiratory tract infection viral, rhinitis, pharyngitis, respiratory tract infection, metapneumovirus infection, tracheobronchitis, viral upper respiratory tract infection, laryngitis, respiratory syncytial virus infection, staphylococcal pharyngitis, tonsillitis, viral pharyngitis, acute sinusitis, nasopharyngitis, bronchiolitis, bronchitis viral, pharyngitis streptococcal, tracheitis, upper respiratory tract infection bacterial, bronchitis bacterial, epiglottitis, laryngitis viral, oropharyngeal candidiasis, respiratory moniliasis, viral rhinitis, acute tonsillitis, rhinovirus infection. Cough, productive cough, allergic cough. Dyspnea, dyspnea exertional. Note: ARs that occurred in 10% of patients and with at least 5% greater frequency in the DARZALEX + Vd arm are listed. 13
14 DARZALEX (daratumumab) + pomalidomide + dexamethasone (DPd) DOSING & SAFETY
15 DARZALEX (daratumumab) + Pd dosing In patients with 2 prior lines of therapy including lenalidomide and a proteasome inhibitor (PI) 1 Dosing schedule based on a phase 1b, open-label trial 1,4 DARZALEX in combination with Pomalyst (pomalidomide) and dexamethasone (Pd) [N=103] 1 Important information 1 DARZALEX should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur If a planned dose of DARZALEX is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval Recommended dosage and schedule 1 DARZALEX is given as an intravenous (IV) infusion after dilution at 16 mg/kg of actual body weight, with pre- and post-infusion medications See table on next page Pomalyst (pomalidomide) is given orally on days 1 21 of each cycle* Dexamethasone 40 mg is given orally or IV once a week On DARZALEX infusion days, 20 mg of the dexamethasone dose was given as a preinfusion medication and the remainder given the day after the infusion For patients on a reduced dexamethasone dose, the entire 20-mg dose was given as a DARZALEX pre-infusion medication DRUG INTERACTIONS Effect of Other Drugs on Daratumumab: The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab. Effect of Daratumumab on Other Drugs: The coadministration of DARZALEX with bortezomib did not affect the pharmacokinetics of bortezomib. Pomalyst is a registered trademark of Celgene Corporation. * Please refer to the pomalidomide Prescribing Information for more detailed information about pomalidomide dosing. Dexamethasone dosing may be modified for various patient populations. Please see the DARZALEX Prescribing Information for more information. 15
16 DARZALEX + Pd dosing schedule Dosing frequency of DARZALEX decreases throughout the course of therapy 1 Cycles 1 2 (each lasting 28 days) Total of 8 DARZALEX doses Day DARZALEX weekly pomalidomide dexamethasone Rest Cycles 3 6 (each lasting 28 days) Total of 8 DARZALEX doses Day DARZALEX every 2 weeks pomalidomide dexamethasone Rest Cycle 7+ (each lasting 28 days) Day DARZALEX every 4 weeks pomalidomide dexamethasone Rest Continue DARZALEX + Pd until disease progression or unacceptable toxicity DRUG INTERACTIONS Effect of Other Drugs on Daratumumab: The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab. Effect of Daratumumab on Other Drugs: The coadministration of DARZALEX with bortezomib did not affect the pharmacokinetics of bortezomib. 16
17 Established safety profile with DARZALEX (daratumumab) + Pd Safety demonstrated in combination with Pd The most frequent adverse reactions (ARs) (>20%) with DARZALEX + Pd were fatigue (50%), infusion reactions (50%), upper respiratory tract infection (50%), cough (43%), diarrhea (38%), constipation (33%), dyspnea (33%), nausea (30%), muscle spasms (26%), back pain (25%), pyrexia (25%), insomnia (23%), arthralgia (22%), dizziness (21%), and vomiting (21%) The overall incidence of serious adverse reactions was 49% Serious adverse reactions reported in 5% of patients included pneumonia (7%) Infusion reaction includes terms determined by investigators to be related to infusion. Severe (Grade 3) infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions (any grade; 5%) were nasal congestion, cough, chills, throat irritation, vomiting, and nausea 1 Anemia Treatment-emergent hematology laboratory abnormalities 1 Thrombocytopenia Neutropenia Lymphopenia DARZALEX + Pd N=103 Any grade Grade 3 Grade 4 (%) (%) (%) Discontinuation rates due to ARs with DPd therapy was 13% Neutropenia DARZALEX may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX dose delay may be required to allow recovery of neutrophils. No dose reduction of DARZALEX is recommended. Consider supportive care with growth factors. Thrombocytopenia DARZALEX may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. DARZALEX dose delay may be required to allow recovery of platelets. No dose reduction of DARZALEX is recommended. Consider supportive care with transfusions. 17
18 Safety demonstrated in combination with Pd Adverse reactions with incidence 10% 1 DARZALEX + Pd N=103 Adverse reactions with incidence 10% 1 (cont d) DARZALEX + Pd N=103 AR Any grade (%) Grade 3 (%) Grade 4 (%) AR Any grade (%) Grade 3 (%) Grade 4 (%) Infusion reactions* Gastrointestinal disorders Diarrhea Constipation Nausea Vomiting General disorders and administration site conditions Fatigue Pyrexia Chills Edema peripheral Asthenia Non-cardiac chest pain Pain Infections and infestations Upper respiratory tract infection Pneumonia Metabolism and nutrition disorders Hypokalemia Hyperglycemia Decreased appetite Musculoskeletal and connective tissue disorders Muscle spasms Back pain Arthralgia Pain in extremity Bone pain Musculoskeletal chest pain Nervous system disorders Dizziness Tremor Headache Psychiatric disorders Insomnia Anxiety Respiratory, thoracic, and mediastinal disorders Cough Dyspnea Nasal congestion * Infusion reaction includes terms determined by investigators to be related to infusion. See description of infusion reactions on pages Edema, edema peripheral, peripheral swelling. Acute tonsillitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection. Lung infection, pneumonia, pneumonia aspiration. Cough, productive cough, allergic cough. Dyspnea, dyspnea exertional. 18
19 MONOTHERAPY (single agent) DOSING & SAFETY
20 DARZALEX (daratumumab) dosing Important information 1 DARZALEX should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur If a planned dose of DARZALEX is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval Recommended dosage and schedule 1 DARZALEX is given as an intravenous (IV) infusion after dilution at 16 mg/kg of actual body weight, with pre- and post-infusion medications See table on next page Administer DARZALEX only as an IV infusion after dilution Interference with Determination of Complete Response Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein. 20
21 DARZALEX dosing schedule Dosing frequency of DARZALEX decreases throughout the course of therapy 1 DRUG INTERACTIONS Effect of Other Drugs on Daratumumab: The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab. Effect of Daratumumab on Other Drugs: The coadministration of DARZALEX with bortezomib did not affect the pharmacokinetics of bortezomib. 21
22 Established safety profile with DARZALEX (daratumumab)* * Safety data were pooled from 3 open-label clinical studies of relapsed/refractory patients treated with 16 mg/kg DARZALEX (N=156). 1 Pneumonia also includes the terms streptococcal pneumonia and lobar pneumonia. Infusion reaction includes terms determined by investigators to be related to infusion. Severe (Grade 3) infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions (any grade; 5%) were nasal congestion, cough, chills, throat irritation, nausea and vomiting 1 Adverse reactions resulted in treatment delay for 24 patients (15%), most frequently for infections. Adverse reactions resulted in discontinuations for 6 patients (4%) Neutropenia DARZALEX may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX dose delay may be required to allow recovery of neutrophils. No dose reduction of DARZALEX is recommended. Consider supportive care with growth factors. Thrombocytopenia DARZALEX may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. DARZALEX dose delay may be required to allow recovery of platelets. No dose reduction of DARZALEX is recommended. Consider supportive care with transfusions. 22
23 Indications and INDICATIONS DARZALEX is indicated: in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS Infusion Reactions DARZALEX can cause severe infusion reactions. Approximately half of all patients experienced a reaction, most during the first infusion. Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing an infusion. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt infusion for reactions of any severity and institute medical management as needed. Permanently discontinue therapy for life-threatening (Grade 4) reactions. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion. Infusion Reactions (cont d) To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients following DARZALEX infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and longacting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. Interference with Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient s serum. The determination of a patient s ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX. Type and screen patients prior to starting DARZALEX. Neutropenia DARZALEX may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX dose delay may be required to allow recovery neutrophils. No dose reduction of DARZALEX is recommended. Consider supportive care with growth factors. Thrombocytopenia DARZALEX may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer s prescribing information for background therapies. DARZALEX dose delay may be required to allow recovery of platelets. No dose reduction of DARZALEX is recommended. Consider supportive care with transfusions. Please see additional on page 24 23
24 Indications and (cont d) Interference with Determination of Complete Response Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein. Adverse Reactions The most frequently reported adverse reactions (incidence 20%) in clinical trials were: infusion reactions, neutropenia, thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy and upper respiratory tract infection. In patients who received DARZALEX in combination with lenalidomide and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: upper respiratory tract infection (65%), infusion reactions (48%), diarrhea (43%), fatigue (35%), cough (30%), muscle spasms (26%), nausea (24%), dyspnea (21%) and pyrexia (20%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions were pneumonia (12%), upper respiratory tract infection (7%), influenza (3%) and pyrexia (3%). DARZALEX in combination with lenalidomide and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were neutropenia (36%) and lymphopenia (42%). In patients who received DARZALEX in combination with bortezomib and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: peripheral sensory neuropathy (47%), infusion reactions (45%), upper respiratory tract infection (44%), diarrhea (32%), cough (27%), peripheral edema (22%), and dyspnea (21%). The overall incidence of serious adverse reactions was 42%. Serious adverse reactions were upper respiratory tract infection (5%), diarrhea (2%) and atrial fibrillation (2%). DARZALEX in combination with bortezomib and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were lymphopenia (41%) and thrombocytopenia (28%). Adverse Reactions (cont d) In patients who received DARZALEX as monotherapy, the most frequently reported adverse reactions (incidence 20%) were: infusion reactions (48%), fatigue (39%), nausea (27%), back pain (23%), pyrexia (21%), cough (21%), and upper respiratory tract infection (20%). Serious adverse reactions were reported in 51 (33%) patients. The most frequent serious adverse reactions were pneumonia (6%), general physical health deterioration (3%), and pyrexia (3%). DARZALEX as monotherapy: treatmentemergent Grade 3-4 hematology laboratory abnormalities 20% was lymphopenia (30%). In patients who received DARZALEX in combination with pomalidomide and dexamethasone, the most frequent adverse reactions (>20%) were fatigue (50%), infusion reactions (50%), upper respiratory tract infection (50%), cough (43%), diarrhea (38%), constipation (33%), dyspnea (33%), nausea (30%), muscle spasms (26%), back pain (25%), pyrexia (25%), insomnia (23%), arthralgia (22%), dizziness (21%), and vomiting (21%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions reported in 5% patients included pneumonia (7%). DARZALEX in combination with pomalidomide and dexamethasone: treatment-emergent hematology Grade 3-4 laboratory abnormalities 20% were anemia (30%), neutropenia (36%, 46%), and lymphopenia (45%, 26%). DRUG INTERACTIONS Effect of Other Drugs on Daratumumab: The coadministration of lenalidomide, pomalidomide or bortezomib with DARZALEX did not affect the pharmacokinetics of daratumumab. Effect of Daratumumab on Other Drugs: The coadministration of DARZALEX with bortezomib did not affect the pharmacokinetics of bortezomib Please see additional on page 23 24
25 DARZALEX (daratumumab) administration Preparation for administration 1 Prepare the solution for infusion using aseptic technique as follows: Calculate the dose (mg), total volume (ml) of DARZALEX solution required, and number of DARZALEX vials needed based on patient s actual body weight Check that the DARZALEX solution is colorless to pale yellow. Do not use if opaque particles, discoloration, or foreign particles are present Remove a volume of 0.9% Sodium Chloride Injection, USP, from the infusion bag/container that is equal to the required volume of DARZALEX solution Withdraw necessary amount of DARZALEX solution and dilute to appropriate volume by adding to the infusion bag/container containing 0.9% Sodium Chloride Injection, USP. Infusion bags/containers must be made of either polyvinylchloride (PVC), polypropylene (PP), polyethylene (PE), or polyolefin blend (PP+PE). Dilute under appropriate conditions. Discard any unused portion left in the vial Gently invert the bag/container to mix the solution. Do not shake Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The diluted solution may develop very small, translucent to white proteinaceous particles, as DARZALEX is a protein. Do not use if visibly opaque particles, discoloration, or foreign particles are observed Since DARZALEX does not contain a preservative, administer the diluted solution immediately at room temperature, 15 C to 25 C (59 F to 77 F), and in room light. Diluted solution may be kept at room temperature for a maximum of 15 hours (including infusion time) If not used immediately, the diluted solution can be stored prior to administration for up to 24 hours at refrigerated conditions, 2 C to 8 C (36 F to 46 F), and protected from light. Do not freeze Adverse Reactions The most frequently reported adverse reactions (incidence 20%) in clinical trials were: infusion reactions, neutropenia, thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy and upper respiratory tract infection. In patients who received DARZALEX in combination with lenalidomide and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: upper respiratory tract infection (65%), infusion reactions (48%), diarrhea (43%), fatigue (35%), cough (30%), muscle spasms (26%), nausea (24%), dyspnea (21%) and pyrexia (20%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions were pneumonia (12%), upper respiratory tract infection (7%), influenza (3%) and pyrexia (3%). DARZALEX in combination with lenalidomide and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were neutropenia (36%) and lymphopenia (42%). In patients who received DARZALEX in combination with bortezomib and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: peripheral sensory neuropathy (47%), infusion reactions (45%), upper respiratory tract infection (44%), diarrhea (32%), cough (27%), peripheral edema (22%), and dyspnea (21%). The overall incidence of serious adverse reactions was 42%. Serious adverse reactions were upper respiratory tract infection (5%), diarrhea (2%) and atrial fibrillation (2%). DARZALEX in combination with bortezomib and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were lymphopenia (41%) and thrombocytopenia (28%). 25
26 DARZALEX (daratumumab) administration (cont d) Administration 1 If stored in the refrigerator, allow the solution to come to room temperature. Administer diluted solution by intravenous (IV) infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, nonpyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.22 or 0.2 micrometer). Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), PVC, PP, or PE Do not store any unused portion of the infusion solution for reuse. Any unused product or waste material should be disposed of in accordance with local requirements Do not infuse DARZALEX concomitantly in the same IV line with other agents Adverse Reactions In patients who received DARZALEX as monotherapy, the most frequently reported adverse reactions (incidence 20%) were: infusion reactions (48%), fatigue (39%), nausea (27%), back pain (23%), pyrexia (21%), cough (21%), and upper respiratory tract infection (20%). Serious adverse reactions were reported in 51 (33%) patients. The most frequent serious adverse reactions were pneumonia (6%), general physical health deterioration (3%), and pyrexia (3%). DARZALEX as monotherapy: treatmentemergent Grade 3-4 hematology laboratory abnormalities 20% was lymphopenia (30%). In patients who received DARZALEX in combination with pomalidomide and dexamethasone, the most frequent adverse reactions (>20%) were fatigue (50%), infusion reactions (50%), upper respiratory tract infection (50%), cough (43%), diarrhea (38%), constipation (33%), dyspnea (33%), nausea (30%), muscle spasms (26%), back pain (25%), pyrexia (25%), insomnia (23%), arthralgia (22%), dizziness (21%), and vomiting (21%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions reported in 5% patients included pneumonia (7%). DARZALEX in combination with pomalidomide and dexamethasone: treatment-emergent hematology Grade 3-4 laboratory abnormalities 20% were anemia (30%), neutropenia (36%, 46%), and lymphopenia (45%, 26%). 26
27 Infusion rates for DARZALEX (daratumumab) Slower rate of infusion for the first DARZALEX dose is recommended, as infusion reactions are more likely to occur with the first infusion 1 * Use a dilution volume of 500 ml only if there were no Grade 1 (mild) or greater infusion reactions during the first 3 hours of the first infusion. Otherwise, continue to use a dilution volume of 1000 ml and instructions for the first infusion. Use a modified initial rate for subsequent infusions (ie, third infusion onwards) only if there were no Grade 1 (mild) or greater infusion reactions during a final infusion rate of 100 ml/hour in the first two infusions. Otherwise, continue to use instructions for the second infusion. Consider incremental escalation of the infusion rate only in the absence of infusion reactions. Infusion Reactions DARZALEX can cause severe infusion reactions. Approximately half of all patients experienced a reaction, most during the first infusion. Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing an infusion. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt infusion for reactions of any severity and institute medical management as needed. Permanently discontinue therapy for life-threatening (Grade 4) reactions. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion. Median infusion duration decreased considerably after the first infusion across all trials (n=820) 1 First infusion was 7.0 hours Second infusion was 4.3 hours Subsequent infusions were 3.5 hours Administration of pre- and post-infusion medications is recommended to reduce the risk of infusion reactions (see pages 40 41) 1 27
28 48% of patients experienced an infusion reaction Across all trials (n=820), most infusion reactions occurred during the first infusion 1 For 46% of patients, infusion reactions (any grade) occurred with the first infusion, 2% of patients with the second infusion, and 3% of patients with subsequent infusions 1 The median time to onset of an infusion reaction was 1.4 hours (range: 0.02 to 72.8 hours) 1 Incidence of infusion modification due to reactions was 42% 1 DARZALEX (daratumumab) can cause severe infusion reactions. Severe (Grade 3) infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions (any grade; 5%) were nasal congestion, cough, chills, throat irritation, vomiting, and nausea 1 Infusion reactions of any grade or severity may be managed by interruption, modification, and/or discontinuation of the infusion 1 Infusion reactions by grade (n=820) 1 Infusion Reactions (cont d) To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients following DARZALEX infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and longacting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. 28
29 Management of infusion reactions Infusion reactions of any grade or severity may be managed by interruption, modification, and/or discontinuation of the infusion 1 For infusion reactions of any grade/severity, immediately interrupt the DARZALEX (daratumumab) infusion and manage symptoms. Management of infusion reactions may further require reduction in the rate of infusion or treatment discontinuation of DARZALEX as outlined below Infusion Reactions DARZALEX can cause severe infusion reactions. Approximately half of all patients experienced a reaction, most during the first infusion. Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing an infusion. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt infusion for reactions of any severity and institute medical management as needed. Permanently discontinue therapy for life-threatening (Grade 4) reactions. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion. To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients following DARZALEX infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and longacting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease. 29
30 Important information before administering DARZALEX (daratumumab) Interference with serological testing 1 DARZALEX binds to CD38 found on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test) that may persist for up to 6 months after the last DARZALEX infusion Reminders Type and screen patients before starting DARZALEX Inform blood banks when a patient is taking DARZALEX Identify any DARZALEX -treated blood samples Ask patients to tell other healthcare professionals that they have taken DARZALEX Adverse Reactions The most frequently reported adverse reactions (incidence 20%) in clinical trials were: infusion reactions, neutropenia, thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy and upper respiratory tract infection. In patients who received DARZALEX in combination with lenalidomide and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: upper respiratory tract infection (65%), infusion reactions (48%), diarrhea (43%), fatigue (35%), cough (30%), muscle spasms (26%), nausea (24%), dyspnea (21%) and pyrexia (20%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions were pneumonia (12%), upper respiratory tract infection (7%), influenza (3%) and pyrexia (3%). DARZALEX in combination with lenalidomide and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were neutropenia (36%) and lymphopenia (42%). Prophylaxis for herpes zoster reactivation 1 Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week of starting DARZALEX and continue for 3 months following treatment Pre-infusion medications are recommended 1 Pre-infusion medications To reduce the risk of infusion reactions, administer approximately 1 3 hours prior to every infusion as follows: for monotherapy, intravenous (IV) methylprednisolone 100 mg, or equivalent. Following the second infusion, the dose of corticosteroid may be reduced (oral or IV methylprednisolone 60 mg) for combination therapy, IV dexamethasone 20 mg prior to the first infusion and IV or oral dexamethasone 20 mg prior to subsequent infusions oral antipyretics (acetaminophen 650 mg to 1000 mg), plus oral or IV antihistamine (diphenhydramine 25 mg to 50 mg or equivalent) Note: On DARZALEX infusion days in combination therapy clinical trials, 20 mg of the dexamethasone dose was given as a pre-infusion medication. For patients on a reduced dexamethasone dose, the entire 20-mg dose was given as a DARZALEX pre-infusion medication. In patients who received DARZALEX in combination with bortezomib and dexamethasone, the most frequently reported adverse reactions (incidence 20%) were: peripheral sensory neuropathy (47%), infusion reactions (45%), upper respiratory tract infection (44%), diarrhea (32%), cough (27%), peripheral edema (22%), and dyspnea (21%). The overall incidence of serious adverse reactions was 42%. Serious adverse reactions were upper respiratory tract infection (5%), diarrhea (2%) and atrial fibrillation (2%). DARZALEX in combination with bortezomib and dexamethasone: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% were lymphopenia (41%) and thrombocytopenia (28%). 30
31 Post-infusion medications are recommended Post-infusion medications To reduce the risk of delayed infusion reactions, administer after every infusion as follows 1 : oral corticosteroid for monotherapy, 20 mg methylprednisolone or equivalent dose of an intermediate-acting or long-acting corticosteroid in accordance with local standards on each of the 2 days following all DARZALEX (daratumumab) infusions (beginning the day after the infusion) for combination therapy, 20 mg of methylprednisolone or equivalent the day after the DARZALEX infusion; however, if a background regimen-specific corticosteroid (eg, dexamethasone) is administered the day after the DARZALEX infusion, additional post-infusion medications may not be needed Note: For patients with a history of chronic obstructive pulmonary disease, consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids. Following the first 4 infusions, if the patient experiences no major infusion reactions, these additional inhaled post-infusion medications may be discontinued. Interference with Determination of Complete Response Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein. In patients who received DARZALEX as monotherapy, the most frequently reported adverse reactions (incidence 20%) were: infusion reactions (48%), fatigue (39%), nausea (27%), back pain (23%), pyrexia (21%), cough (21%), and upper respiratory tract infection (20%). Serious adverse reactions were reported in 51 (33%) patients. The most frequent serious adverse reactions were pneumonia (6%), general physical health deterioration (3%), and pyrexia (3%). DARZALEX as monotherapy: treatment-emergent Grade 3-4 hematology laboratory abnormalities 20% was lymphopenia (30%). In patients In patients who received DARZALEX in combination with pomalidomide and dexamethasone, the most frequent adverse reactions (>20%) were fatigue (50%), infusion reactions (50%), upper respiratory tract infection (50%), cough (43%), diarrhea (38%), constipation (33%), dyspnea (33%), nausea (30%), muscle spasms (26%), back pain (25%), pyrexia (25%), insomnia (23%), arthralgia (22%), dizziness (21%), and vomiting (21%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions reported in 5% patients included pneumonia (7%). DARZALEX in combination with pomalidomide and dexamethasone: treatment-emergent hematology Grade 3-4 laboratory abnormalities 20% were anemia (30%), neutropenia (36%, 46%), and lymphopenia (45%, 26%). 31
progression Monotherapy and in combination with lenalidomide and low-dose dexamethasone: every three weeks (total of 5 doses)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX. DARZALEX (daratumumab)
More informationDARZALEX (daratumumab) injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX. DARZALEX (daratumumab)
More informationDARZALEX. daratumumab PRODUCT INFORMATION. DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number:
NAME OF THE MEDICINE DARZALEX daratumumab PRODUCT INFORMATION DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number: 945721-28-8. DESCRIPTION Daratumumab is an immunoglobulin
More informationDARZALEX. daratumumab NEW ZEALAND DATA SHEET
1 PRODUCT NAME DARZALEX daratumumab NEW ZEALAND DATA SHEET DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml vial contains 100
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)
More informationData featured as a Late-Breaking Abstract at ASH 2018 (Abstract #LBA-2)
Media Inquiries: Brian Kenney Phone: 1-215-620-0111 Satu Glawe Phone: +49 172 294 6264 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr DARZALEX daratumumab 20 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic, monoclonal antibody DARZALEX, indicated
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DARZALEX. daratumumab. 20 mg/ml Concentrate for Solution for Infusion. Professed Standard
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr DARZALEX daratumumab 20 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic, monoclonal antibody Janssen Inc. 19
More informationDRUG NAME: Daratumumab
DRUG NAME: Daratumumab SYNONYM(S): HuMax-CD38 1 COMMON TRADE NAME(S): DARZALEX CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise adult provisions
More informationGAZYVA Dosing and Administration Guide
GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at
More informationADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE INDICATION LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which
More informationDRUG NAME: Daratumumab
DRUG NAME: SYNONYM(S): HuMax-CD38 1 COMMON TRADE NAME(S): DARZALEX CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationYONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE
YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE INDICATION YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received
More informationDOSING AND ORDERING GUIDE
DOSING AND ORDERING GUIDE A reference guide for dosing, ordering, and product returns, plus support services for you and your patients INDICATION EMPLICITI is indicated in combination with lenalidomide
More informationPRODUCT PROFILE. Clinical evidence for formulary and pathway considerations
PRODUCT PROFILE Clinical evidence for formulary and pathway considerations INDICATION EMPLICITI TM (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients
More informationGUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION
GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION Includes Example dose calculation wheel Preparation and administration information for healthcare professionals Please see enclosed full Prescribing Information,
More informationPharmacy Instructions for Preparation
MARQIBO (vincristine sulfate LIPOSOME injection) Pharmacy Instructions for Preparation Important Information for Preparation 1 The instructions for the constitution of MARQIBO are provided in each kit.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Millennium Pharmaceuticals at VELCADE or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VELCADE safely and effectively. See full prescribing information for VELCADE. VELCADE (bortezomib)
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationTo learn more, visit ISTODAX.com or speak with your local Celgene representative
DOSING GUIDE FOR NURSES AND PHARMACISTS Important facts you should know about: Dosing Dosing Modifications Administration Safety To learn more, visit ISTODAX.com or speak with your local Celgene representative
More informationHERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab)
More informationLEMTRADA REMS Education Program for Healthcare Facilities
For Healthcare Facilities LEMTRADA REMS Education Program for Healthcare Facilities This Educational Piece Includes Information About: The LEMTRADA REMS Program requirements to implement in your healthcare
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX. DARZALEX (daratumumab)
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr Empliciti TM (em-plis-city) (elotuzumab 300 & 400 mg powder for concentrate for solution for infusion) Read this
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationIn HER2+ breast cancer: 2 INDICATIONS. PERJETA + Herceptin-based therapy dosing durations 1 CONTINUE UNTIL PROGRESSION OR UNACCEPTABLE TOXICITY
Recommended dosing for PERJETA + Herceptin-based treatment in HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY METASTATIC: Administer every 3 weeks until disease progression
More informationREVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED APPROVAL BY FDA FOR TREATMENT OF MULTIPLE MYELOMA
Contact: Robert J. Hugin Brian P. Gill President and COO Senior Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED
More informationINFUSING. ORENCIA (abatacept) IV INDICATION/USAGE. Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion
INFUSING ORENCIA (abatacept) IV Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA is indicated for reducing
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationIn first-line HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY
In first-line HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY The most common adverse reactions (>30) with PERJETA in combination with trastuzumab and docetaxel were diarrhea,
More informationTaiwan PI for Velcade. (Followed as USPI version Jun 2017; Local version 1701)
Taiwan PI for Velcade (Followed as USPI version Jun 2017; Local version 1701) 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Multiple Myeloma Velcade (bortezomib) in combination with other
More informationCONTRAINDICATIONS None. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. ARZERRA (ofatumumab)
More informationBLA /S-017 BLA /S-018 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125486/S-017 BLA 125486/S-018 SUPPLEMENT APPROVAL Genentech, Inc. Attention: Jerald Grace, PharmD Regulatory
More informationFOR TREATMENT OF PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) KANUMA (sebelipase alfa) DOSING AND ADMINISTRATION GUIDE
FOR TREATMENT OF PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) KANUMA (sebelipase alfa) DOSING AND ADMINISTRATION GUIDE Please see Important Safety Information on page 8 and the attached full
More informationPNH ahus gmg. Dosing and Administration Guide
Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration
More informationDOSAGE FORMS AND STRENGTHS mg/40 ml (25 mg/ml) single-dose vial. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. GAZYVA (obinutuzumab)
More information(galsulfase) DOSING & ADMINISTRATION GUIDE
(galsulfase) DOSING & ADMINISTRATION GUIDE Indication: (galsulfase) is indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). has been shown to improve walking and stair-climbing
More informationPHARMACY DOSING AND ORDERING GUIDE
PHARMACY DOSING AND ORDERING GUIDE FIRST AND ONLY APPROVED TREATMENT FOR PATIENTS WITH VOD WITH RENAL OR PULMONARY DYSFUNCTION POST HSCT VOD=veno-occlusive disease Indication Defitelio (defibrotide sodium)
More informationA Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION
A Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION CYRAMZA (ramucirumab), in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VELCADE safely and effectively. See full prescribing information for VELCADE. VELCADE (bortezomib)
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOmalizumab vs. Mepolizumab for Asthma Patients: How to Decide. Indications
vs. for Asthma Patients: How to Decide Indications Asthma is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity
More informationPackage leaflet: Information for the patient. SYLVANT 400 mg powder for concentrate for solution for infusion. siltuximab
Package leaflet: Information for the patient SYLVANT 400 mg powder for concentrate for solution for infusion siltuximab This medicine is subject to additional monitoring. This will allow quick identification
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr Kyprolis carfilzomib for injection 10, 30, 60 mg per vial Antineoplastic Agent Amgen Canada Inc. 6775 Financial Drive, Suite 100 Mississauga,
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationStep-by-step instructions for intravenous (iv) infusions for patients with:
Step-by-step instructions for intravenous (iv) infusions for patients with: Rheumatoid Arthritis (RA) Systemic Juvenile Idiopathic Arthritis (sjia) Polyarticular Juvenile Idiopathic Arthritis (pjia) Please
More informationPNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients
For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationAdministration Tear Pad
for WG and Administration Tear Pad The first and ONLy FDA-approved therapy for Wegener s granulomatosis (WG) AND microscopic polyangiitis () Inside: Patient Checklist and Chart Record Preparation and Administration
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationThe only biologic approved to treat SLE: now with multiple delivery options
The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PERJETA safely and effectively. See full prescribing information for PERJETA. PERJETA (pertuzumab)
More informationStaying on Track With Your Treatments
Staying on Track With Your Treatments You will receive along with two other prescription medicines called REVLIMID (lenalidomide) and dexamethasone. Filling out these calendars can help you and your healthcare
More informationPACKAGE INSERT USP ANTIBIOTIC
Pr AMPICILLIN for Injection USP ANTIBIOTIC ACTIONS AND CLINICAL PHARMACOLOGY Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gramnegative aerobic and anaerobic bacteria.
More information*Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI. for injection,
More informationZYDELIG PBS. (idelalisib) RETHINK WHAT S POSSIBLE... LISTED 1
RETHINK WHAT S POSSIBLE... ZYDELIG (idelalisib) PBS LISTED 1 st 1 September 2017 ZYDELIG a first-in-class oral PI3Kδ inhibitor is PBS listed from 1 st September 2017 for the treatment of: Double-refractory
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationAUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab)
AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab) WARNING Progressive Multifocal Leucoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) including fatal PML can occur in patients receiving
More informationACTEMRA SC formulation is not intended for intravenous administration.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationACTEMRA can be used alone following discontinuation of glucocorticoids.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (tocilizumab) injection, for intravenous
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. ADCETRIS (brentuximab
More informationCONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. PRC-498 IMBRUVICA
More informationWHO PACKAGE INSERT. GlaxoSmithKline Biologicals FluLaval. Dossier First - Chapter 1 to 10 for WHO
77 WHO PACKAGE INSERT 11 Chapter 4_Annex 4.4-1_ WHO leaflet_en - Page 1 78 1. NAME OF THE MEDICINAL PRODUCT, suspension for injection Influenza vaccine (split virion, inactivated) 2. QUALITATIVE AND QUANTITATIVE
More informationGAZYVA for Previously Untreated Follicular Lymphoma
NOW APPROVED GAZYVA for Previously Untreated Follicular Lymphoma Studied head-to-head vs rituximab * in stage II bulky, III, and IV patients 1 * GAZYVA and rituximab were each combined with bendamustine,
More informationPreparation and Administration
Preparation and Administration A guide for healthcare professionals XOLAIR IS INDICATED FOR: Adults and adolescents (aged 12 years) with moderate-to-severe persistent asthma who have a positive skin test
More informationDOSING AND INFORMATION GUIDE LEAPS AHEAD
DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME
More informationDosing and Administration Guide
Dosing and Administration Guide NULOJIX (belatacept) is available as 250 mg lyophilized powder for injection, for intravenous use. Indication r NULOJIX (in combination with basiliximab induction, mycophenolate
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationREVLIMID [lenalidomide] capsules, for oral use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide]
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Millennium Pharmaceuticals at VELCADE or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VELCADE safely and effectively. See full prescribing information for VELCADE. VELCADE (bortezomib)
More informationPackage leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase
Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new
More informationACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationStudent Health Center
Referring Allergist Agreement Your patient is requesting that the University of Mary Washington Student Health Center (UMWSHC) administer allergy extracts provided by your office. Consistent with our policies
More informationReceiving PERJETA + Herceptinbased therapy * after surgery
Treatment after surgery for HER2+ early breast cancer that has a high risk of coming back Receiving PERJETA + Herceptinbased therapy * after surgery PERJETA is part of an FDA-approved treatment regimen
More informationInfusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis
Infusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis 1 PREINFUSION COUNSELING Provide medication guide and review with your patient Inform patients about the signs
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationCost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationWARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) See full prescribing information for complete boxed warning.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. for injection, for
More informationFuel your determination to live longer with KYPROLIS. Look inside to learn more.
F O R R E L A P S E D MULT IP L E M Y E L OM A APPROVED USES KYPROLIS is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous
More informationACTEMRA IV Dosing & Administration Pocket Guide
IMPORTANT SAFETY INFORMATION BOXED WARNING Serious Infections Serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic
More informationKYPROLIS Injection 60 mg/vial, 30 mg/vial (carfilzomib)
Prescription only 421: Anti-malignant tumor agent KYPROLIS Injection 60 mg/vial, 30 mg/vial (carfilzomib) [COMPOSITION] [60 mg Drug Product] 1 vial contains Active Ingredient: carfilzomib (in-house) 61.8
More informationPackage leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab
Package leaflet: Information for the user ReoPro 2 mg/ml solution for injection or infusion abciximab Read all of this leaflet carefully before you start using this medicine because it contains important
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDosing & Administration Coding & Billing
Reference Guide Dosing & Administration Coding & Billing INDICATION For more information, call Gaucher Personal Support (GPS) toll free at 1-855-ELELYSO (1-855-353-5976) or visit ELELYSOHCP.com. ELELYSO
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GAMMANORM, 165 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg) Human
More informationPeople who have received 1-3 prior treatments for their multiple myeloma may receive: Revlimid (lenalidomide)
FINDTHE THE FIND STRENGTH STRENGTH WITHIN WITHIN TOHELP HELPFIGHT FIGHT TO MULTIPLEMYELOMA MYELOMA MULTIPLE Rick N. N. patient Rick patient What is? is a prescription medicine used with other medications
More informationCEREZYME Genzyme. 70 mg (52 mg) (18 mg)
CEREZYME Genzyme Imiglucerase for injection 400 UNITS 200 UNITS DESCRIPTION Cerezyme (imiglucerase for injection) is an analogue of the human enzyme ß-Glucocerebrosidase, produced by recombinant DNA technology.
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE for ADCETRIS in classical Hodgkin lymphoma (chl) ADCETRIS is indicated for the treatment of: Previously untreated Stage III/IV chl Adult patients with previously untreated
More informationWhat You Need to Know About ARZERRA (ofatumumab)
Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil
More information